South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and manufacturing organization (CDMO) to cytotoxic drugs.
Under the agreement, Boryung will manufacture an anticancer injection for Lotus.
The company plans to supply the agent to Lotus starting in 2026.
The product name will be disclosed by agreement between the two companies.
Boryung will manufacture the anticancer drug at its EU-GMP-certified plant in Yesan, South Chungcheong Province.
The facility, designed by Novo Nordisk Engineering (NNE), can produce 6 million vials annually.
Write to Ji-Hyun Lee at bluesky@hankyung.com
Intuitive Machines' Nova-C class lunar lander (Courtesy of Intuitive Machines) South Korea's Boryung Corp. said on Friday it bought $10.0 million in shares of US-based lunar lander company Intuitive Machines to expand its space healthcare business.The company participated in Intuitive Machines'
A consortium of Eugene Private Equity and Korea Development Bank Private Equity will acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won ($231 million).According to investment banking sources on Thursday, the Eugene PE-KDB PE consortium will sign a share purchas